Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Arsenicals in hematologic cancers.

S C Novick1, R P Warrell

  • 1Leukemia and Developmental Chemotherapy Services, Memorial Sloan-Kettering Cancer Center, and the Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA.

Seminars in Oncology
|October 26, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide.

Leukemia·2004
Same author

Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.

The Journal of clinical investigation·2001
Same author

Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia.

Blood·2001
Same author

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.

Current oncology reports·2000
Same author

Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery.

Cancer chemotherapy and pharmacology·2000

Arsenic trioxide (AT) effectively treats acute promyelocytic leukemia (APL), achieving high remission rates in relapsed or refractory cases. Further research explores AT combinations and broader applications in other cancers.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Arsenic trioxide (AT) has resurfaced as a significant therapeutic agent.
  • Initial studies in China during the late 1980s highlighted its efficacy in treating acute promyelocytic leukemia (APL).

Purpose of the Study:

  • To review the efficacy and tolerability of arsenic trioxide in APL treatment.
  • To discuss ongoing research into pharmacokinetics, mechanisms of action, and potential new applications of AT.

Main Methods:

  • Review of clinical studies on arsenic trioxide for APL.
  • Analysis of reported side effects and treatment outcomes.
  • Examination of pharmacokinetic and dose-ranging trials.

Main Results:

Related Experiment Videos

  • Complete remission rates of 80%-90% in refractory/relapsed APL patients.
  • AT is generally well-tolerated at the APL treatment dose (0.15 mg/kg/d), which is below the maximum-tolerated dose (MTD).
  • Common side effects include fatigue, rash, fluid retention, and QTc prolongation; a retinoic acid syndrome has also been observed.

Conclusions:

  • Arsenic trioxide is a highly effective treatment for APL.
  • Future research directions include combining AT with all-trans retinoic acid (RA) for newly diagnosed APL and investigating AT for other hematologic malignancies and solid tumors.